The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis

Part of paid clinical trials in Frisco, Texas.

Sponsor
TricelX Inc.
Study ID
NCT07487766
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Mesenchymal Stem Cell Injection — BIOLOGICAL
    Subjects will receive an intra-articular injection of mesenchymal stem cells derived from umbilical cord tissue

Study Details

This study aims to study the safety and efficacy of XytriX, an umbilical cord-derived stem cell product, in the treatment of Grade I-IV knee osteoarthritis.

Key Dates

Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
May 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: XytriX 30 million cells intra-articular injection
    Subjects in this arm are receiving the drug at a 30 million cells IA dose.
  • Experimental: XytriX 10 million cells IA Injection
  • Experimental: XytriX 50 million cells IA dose

Primary Outcome Measure

Knee Injury and Osteoarthritis Outcome Score [ Time Frame: 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
TriCelXFriscoTexas75034
Kathryn Dziedzic
[email protected]
855-874-2359

Find similar trials in Frisco, TX

By condition
Osteoarthritis (other)
By specialty
OrthopedicsMusculoskeletal disorders
By research site
TriCelX· Frisco, TX

Related Studies